Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior
|
|
- Branden Holland
- 6 years ago
- Views:
Transcription
1 Article / Clinical Case Reports Artigo / Relato de Caso Clínico Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior Leonardo Gomes da Fonseca a, Ciro Eduardo Souza a, Romulo Loss Mattedi b, Daniel Motta Girardi a, Álvaro Sadek Sarkis c, Paulo Marcelo Gem Hoff a Fonseca LG, Souza CE, Mattedi RL, Girardi DM, Sarkis AS, Hoff PMG. Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior. Autopsy Case Rep [Internet]. 2014;4(4): dx.doi.org/ /acr ABSTRACT Plasmocytoid variant urothelial carcinoma (PVUC) of the urinary bladder is a rare histological variant of transitional cell carcinoma. Data regarding PVUC shows that this neoplasia presents a distinctive clinical outcome represented by aggressive behavior and poor survival rate. The authors report a case of a 57-year-old male patient with a 3-month history of hematuria and pelvic pain. Radical cystectomy with lymphadenectomy was performed and pathological examination showed a pt3pn0 PVUC of the bladder. The patient remained free of recurrence for 8 months, but the disease recurred involving the abdominal wall and subcutaneous tissue. Chemotherapy provided a positive clinical response and relief of symptoms. The authors call attention to the aggressiveness of this rare variant of bladder cancer and recommend radical surgery and multidisciplinary management of this neoplasm. Keywords Carcinoma; Urothelium; Urinary Bladder Neoplasms; Cystectomy. CASE REPORT A 57-year-old man sought the Urology Service complaining of pelvic pain and hematuria for three months. His past medical history included heavy smoking. No familial history of cancer was present. The first diagnostic approach involved a cystoscopy, which revealed thickened urinary bladder mucosa. Therefore he was submitted to transurethral resection, which showed a muscle-invasive urothelial carcinoma on histological examination. Initial pelvic, abdominal and thoracic computed tomography (CT) showed bladder wall thickening (Figure 1) without regional or distant lymphadenopathy neither distant metastasis. A radical cystectomy with lymphadenectomy was performed. Pathological examination showed plasmocytoid urothelial carcinoma invading perivesical adipose tissue and anterior bladder wall. (Figure 2) The urethral margins were tumor free but perineural invasion was present. No tumoral involvement was observed in 9 dissected lymph nodes. The immunohistochemistry study revealed positivity to cytokeratin CK7, CK20, 34bE12 and CD138. Napsin A, CDX-2, p63 and E-cadherin were negative. Pathological staging was pt3pn0. (Figure 3) a Department of Clinical Oncology - Instituto do Câncer do Estado de São Paulo - São Paulo/SP, Brazil. b Department of Pathology - Instituto do Câncer do Estado de São Paulo - São Paulo/SP, Brazil. c Department of Urology - Instituto do Câncer do Estado de São Paulo - São Paulo/SP, Brazil. Autopsy and Case Reports. ISSN Copyright This is an Open Access article distributed of terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted noncommercial use, distribution, and reproduction in any medium provided article is properly cited.
2 Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior After 8 months, the patient presented progressive swelling and pain in the suprapubic region and scrotum. CT scan showed a densification of adipose and muscle layers of the anterior abdominal wall extending to the scrotum. (Figure 4). A biopsy of the subcutaneous adipose tissue confirmed poorly cohesive and plasmocytoid features of the carcinoma compatible with high-grade urothelial carcinoma. (Figure 5) Chemotherapy (MVAC regimen) was prescribed as follow: methotrexate 30 mg/m2 on days 1, 15 and 22; vinblastine 3 mg/m2 on days 2, 15 and 22, doxorubicin 30 mg/m2 on day 2 and cisplatin 70 mg/m2 on day 2, every 28 days each cycle. After 3 cycles, the patients showed marked relief of pain and notably decrease of the suprapubic and scrotal swelling. DISCUSSION In 1991, Sahin et al.1 described the first case of plasmocytoid variant urothelial carcinoma (PVUC) of the bladder in a 63-year-old-man presenting a bladder tumor and multiple lytic bone lesions with histologic appearance that mimicked multiple myeloma. This neoplasm is a rare variant of transitional cell carcinoma. Figure 1. Axial pelvic CT showing bladder wall thickening (arrow). Recently, case series and case reports concerning this carcinoma variant have been published. 2,3 Data regarding PVUC show that this neoplasm presents a distinctive clinical outcome represented by high aggressiveness and poor survival rate.2-4 The number of case reports increased during the last decade, what Figure 2. Photomicrography of the bladder tumor - A - Invasive carcinoma with plasmocytoid features (HE, 100X); B - Detail of tumor cells spread in single cell formation (HE, 200X); C and D - Detail of tumor cells spread in Indian file (HE, 400X). 58
3 Fonseca LG, Souza CE, Mattedi RL, Girardi DM, Sarkis AS, Hoff PMG Figure 3. Photomicrography of the bladder tumor - Immunohistochemistry. A - CD138 positive staining (400x); B - CK34BE12 positive staining (400x); C - E-cadherin negative staining (400x); D - p63 negative staining (400x). Figure 4. Axial CT of the pelvis. A - showing densification of adipose tissue and muscle layers of the anterior abdominal (arrows); B - extension of the infiltration to the scrotum. raised the suspicion of an unrecognized ongoing causative factor or a better recognition of this variant could explain this increment. Histopathological characteristics of PVUC show eccentrically placed nucleus and abundant eosinophilic cytoplasm. Nuclear grade are usually low to intermediate, with occasional pleomorphism. The tumor cells spread in single cell formation, known as Indian file, along nerve bundles. 2,5,6 Immunohistochemical profile of PVUC is characterized by positivity for CD138, a marker shared with myeloma cells. The cell adhesion marker E-cadherin is downregulated, suggesting a possible role of epithelialmesenchymal transition event in PVUC carcinogenesis. Loss of E-cadherin may also allow the discohesive nature of PVUC cells to invade into surrounding tissue, along fascial planes and draining lymph nodes.7 MUM-1 positivity, which occurs in myeloma cells, has not been observed in PVUC.5 Immunohistochemical markers considered specific for urothelial lineage was observed in PVUC in an analysis involving variants of urothelial carcinoma, such 59
4 Plasmacytoid urothelial carcinoma: a case of histological variant of urinary bladder cancer with aggressive behavior Figure 5. A - Carcinoma infiltration of the subcutaneous adipose tissue (HE x 100); B - poorly cohesive and plasmocytoid features consistent with metastatic plasmacytoid carcinoma (HE x400). as GATA3 (100%), S-100P (100%), Thrombomodulin (45%), CK7 (70%), CK20 (60%), p63(54%), HMCK (90%) and uroplakin (8%).8 Although retrospective cohorts studies of tertiary referral centers have been published, there is still paucity of published data on the clinical behavior and treatment of this malignancy. In a recent retrospective analysis, Kaimakliotis et al.9 analyzed 624 patients submitted to radical cystectomy from 2008 to Among them, 25 patients were diagnosed with PVUC. Positive paravesical margins, urethral surgical margins and lymph node involvement were higher in PVUC than in nonvariant subtype. These results indicated more aggressiveness of local spread and called attention for surgeons and pathologists on surgical margins in PVUCs.9 Local treatment for non muscle-invasive bladder urothelial carcinoma is based on transurethral resection with or without intravesical BCG therapy according to high risk factors. Some authors, however, tend to recommend early cystectomy in patients with other urothelial carcinoma variants, such as PVUC, due to the high risk of relapse and aggressive local dissemination.10 Similarly, there is no standard recommendation for initial management of locally-advanced or muscleinvasive PVUC. Dayyani et al. 3 reported the MD Anderson Cancer Center experience with 31 patients with PVUC. Sixteen patients had potentially surgically resectable tumor, 5 of them received neoadjuvant chemotherapy, 10 underwent initial surgery and 1 was treated with transurethral resection. Among the 60 patients who received neoadjuvant chemotherapy, pathological down staging was present in 80%. However, there was no difference in the survival rate between patients that received initial surgery or neoadjuvant chemotherapy. The median survival rate of this cohort was 17.7 months; 45.8 months for stages I-III and 13.3 months for stage IV. Patients with metastatic disease at presentation were treated with chemotherapy and showed the median survival rate of 12.6 months. In this cohort the peritoneum was a common site of recurrence (19 of 23 patients). In other cohort of patients with muscle-invasive bladder tumor after cystectomy, median overall survival rate of patients with PVUC was 22 months, which was significantly lower comparing with patients with nonvariant carcinoma. Therefore, among patients selected for cystectomy, those with PVUC had increased risk of mortality at cystectomy.11 Polychemotherapy regimen MVAC has improved survival and overall response rate in comparison with single-agent cisplastin in randomized phase III trial for metastatic or unresectable urothelial bladder carcinoma.12 There is no consensus nor strong evidence regarding the use of specific chemotherapeutic agents in PVUC. However, in the present case, MVAC regimen provided rapid symptoms relief associated with reasonable tolerance. The aggressive behavior of the present case is in accordance with the literature showing the poor outcome associated with PVUC. Chemotherapy may play a role in disease control and relief of symptoms in unresectable or recurrent disease, as showed in the
5 Fonseca LG, Souza CE, Mattedi RL, Girardi DM, Sarkis AS, Hoff PMG present case. However, neoadjuvant chemotherapy did not seem to impact in long-term survival in the retrospective cohort aforementioned. 11 We believe that early diagnosis and radical surgical approach are pivotal for modifying the clinical course of this subtype of bladder carcinoma. A multidisciplinary team in referral centers is the ideal scenario for managing PVUC treatment. CONCLUSION We presented a case of PVUC, a rare histological variant of urothelial bladder carcinoma. The patient s clinical course is in accordance with the literature data in terms of locally aggressiveness of this tumor. Morphologic distinction of the plasmocytoid phenotype is critical for clinician awareness with regard to the risk for early regional and metastatic progression of the disease. REFERENCES 1. Sahin AA, Myhre M, Ro JY, Sneige N, Dekmezian RH, Ayala AG. Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol. 1991;35(3): PMid: Keck B, Stoehr R, Wach S, et al. The plasmacytoid carcinoma of the bladder rare variant of aggressive urothelial carcinoma. Int J Cancer. 2011;129(2): PMid: Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189(5): juro PMid: Mai KT, Park PC, Yazdi HM, et al. Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases. Eur Urol. 2006;50(5): org/ /j.eururo PMid: Lopez-Beltran A, Requena MJ, Montironi R, Blanca A, Cheng L. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009;40(7): org/ /j.humpath PMid: Raspollini MR, Sardi I, Giunti L, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum Pathol. 2011;42(8): PMid: Erdemir F, Ozcan F, Kilicaslan I, Parlaktas BS, Uluocak N, Gokce O. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol. 2007;39(4): s PMid: Paner GP, Annaiah C, Gulmann C, et al. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol. 2014;45(7): org/ /j.humpath PMid: Kaimakliotis HZ, Monn MF, Cheng L, et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology. 2014;83(5): urology PMid: Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24(5): PMid: Kaimakliotis HZ, Monn MF, Cary KC, et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol. 2014;32(6): PMid: Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7): PMid: Conflict of interest: None Submitted on: September 10, 2014 Accepted on: November 17, 2014 Correspondence Instituto do Câncer do Estado de São Paulo (ICESP) Av. Dr. Arnaldo, 251 São Paulo/SP Brazil CEP: Phone +55 (11) leogfonseca@hotmail.com 61
Plasmacytoid Variant Urothelial Carcinoma: Diagnostic and Grossing Challenges. Kailyn Gibson MS, PA-ASCP, Congli Wang, MD
1 Plasmacytoid Variant Urothelial Carcinoma: Diagnostic and Grossing Challenges Kailyn Gibson MS, PA-ASCP, Congli Wang, MD Johns Hopkins Hospital Department of Surgical Pathology 2 Plasmacytoid Variant
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationUnusual Variants of Bladder Cancer Cristina Magi-Galluzzi, MD, PhD
Unusual Variants of Bladder Cancer Cristina Magi-Galluzzi, MD, PhD Director of Genitourinary Pathology, Professor of Pathology, Lerner College of Medicine Cleveland Clinic Objectives Update on variants
More informationAmerican Journals of Cancer Case Reports. A Rare Case of Rectal Metastasis from Sarcomatoid Variant of Urothelial Carcinoma: A Case Report
American Journals of Cancer Case Reports Lin JYJ et al. American Journals of Cancer Case Reports 2014, 3:1-5 http://ivyunion.org/index.php/ajccr Page 1 of 5 Vol 3 Article ID 20140539, 5 pages Case Report
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationInt J Clin Exp Pathol 2015;8(3): /ISSN: /IJCEP Shogo Tajima 1, Kenji Koda 2
Int J Clin Exp Pathol 2015;8(3):3288-3293 www.ijcep.com /ISSN:1936-2625/IJCEP0005608 Case Report Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection
More informationPlasmacytoid urothelial carcinoma (PUC): Imaging features with histopathological correlation
case series Plasmacytoid urothelial carcinoma (PUC): Imaging features with histopathological correlation Andrew D. Chung, MD; Nicola Schieda, MD; Trevor A. Flood, MD; Ilias Cagiannos, MD; 3 Kien T. Mai,
More informationOrgan-sparing treatment of invasive transitional cell bladder carcinoma
Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationPRIMARY SIGNET RING CELL CARCINOMA OF URINARY BLADDER A RARE CASE WITH RARE PRESENTATION
PRIMARY SIGNET RING CELL CARCINOMA OF URINARY BLADDER A RARE CASE WITH RARE PRESENTATION *R. Sharma 1, A. Sharma 1, N. Ledwani 2 and A. Maurya 1 1 Department of Pathology and 2 Department of Oncosurgery,
More informationKoji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationPure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder
Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationThe changing reality of urothelial bladder cancer: should non-squamous variant. histology be managed as a distinct clinical entity?
The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity? 1 M. Francesca Monn MD MPH# 1, Hristos Z Kaimakliotis MD# 1, K Clint Cary
More informationMicrocystic transitional cell carcinoma: a rare tumor of the urinary bladder
PATHOLOGICA 2017;109:151-155 Case report Microcystic transitional cell carcinoma: a rare tumor of the urinary bladder M. TRIKI 1, L. AYADI 1, R. KALLEL 1, S. CHARFI 1, I. SAGUEM 1, N. MHIRI 2, T.S. BOUDAWARA
More informationImpact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy
www.kjurology.org http://dx.doi.org/./kju... Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=./kju...&domain=pdf&date_stamp= Impact of Histopathological Variant on the Outcome
More informationHow Many Diseases in Carcinoma in situ?
How Many Diseases in Carcinoma in situ? Eva Compérat La Pitié Salpêtrière Assistance Publique Université Pierre et Marie Curie, Paris VI Carcinogenesis of Bladder Cancer (BC) BC is a panurothelial disease
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More information5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.
Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme
More informationPleomorphic Rhabdomyosarcoma Of The Urinary Bladder?mitating A Pelvic Mass: A Case Report
ISPUB.COM The Internet Journal of Urology Volume 11 Number 2 Pleomorphic Rhabdomyosarcoma Of The Urinary Bladder?mitating A Pelvic Mass: A Case Report C Ceylan, T A Serel, A Albayrak, O G Doluoglu Citation
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationCytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis
https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali
More informationPrimary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature
ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T
More informationLarge blocks in prostate and bladder pathology
Large blocks in prostate and bladder pathology Farkas Sükösd Department of Pathology, University of Szeged The history of the large block technique in radical prostatectomy and cystectomy The first large
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationA215- Urinary bladder cancer tissues
A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90
More informationUpdate on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically
More informationInformation for Patients. Bladder Cancer. English
Information for Patients Bladder Cancer English Table of contents What is the function of the bladder?... 3 What is bladder cancer?... 3 What causes bladder cancer?... 3 Stages of the disease... 3 Risk
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationCystoscopy in children presenting with hematuria should not be overlooked
Ped Urol Case Rep 2015; 2(3):7-11 DOI: 10.14534/PUCR.2015310303 PUCR Ped Urol Case Rep PEDIATRIC UROLOGY CASE REPORTS ISSN: 2148 2969 Journal homepage: http://www.pediatricurologycasereports.com Cystoscopy
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More informationBLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR
Med. J. Malaysia Vol. 38. No. I March 1983. BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR ZAKRIYA MAHAMOOTH HUSSAIN AWANG SUMMARY
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationCould salvage surgery after chemotherapy have clinical impact on cancer survival of patients with
Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Kensuke Bekku, Takashi Saika, Yasuyuki Kobayashi, Ryo Kioshimoto, Taiki
More informationUrothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis
Pathology Report With Squamous Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis Yunguang Liu, MD, PhD, Marilyn M. Bui, MD, and Bo Xu, MD, PhD Background: Squamous differentiation occurs
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More informationUreteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor
Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Scott G. Hubosky, MD The Demetrius H. Bagley Jr., MD Associate Professor of Urology Director of Endourology Vice Chair
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationBJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
More informationJ of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 3/ Issue 24/June 16, 2014 Page 6628
ADENOCARCINOMA OF BLADDER-SIGNET RING CELL MUCINOUS VARIANT S. Senthil Kumar 1, D. Prem Charles 2, B. Krishnaswamy 3, P. Viswanathan 4, S. Sarath Chandran 5 HOW TO CITE THIS ARTICLE: S. Senthil Kumar,
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationCorresponding Author: Ahmed A. Al Ibraheemi, Resident in Clinical Oncology, Al Basheer Hospital, Amman, Jordan
IJHOSCR International Journal of Hematology- Oncology and Stem Cell Research Case Report Case report of metastatic invasive breast lobular carcinoma to the urinary bladder Ahmed A. Al Ibraheemi Resident
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationCase Report Renal Cell Carcinoma Metastatic to Thyroid Gland, Presenting Like Anaplastic Carcinoma of Thyroid
Case Reports in Urology Volume 2013, Article ID 651081, 4 pages http://dx.doi.org/10.1155/2013/651081 Case Report Renal Cell Carcinoma Metastatic to Thyroid Gland, Presenting Like Anaplastic Carcinoma
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationInformation for Patients. Primary urethral cancer. English
Information for Patients Primary urethral cancer English Table of contents What is primary urethral cancer?... 3 Risk factors... 3 Symptoms... 4 Diagnosis... 4 Clinical examination... 4 Urinary cytology...
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)
North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Original Prepared by NMcL April 2016
More informationClinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationBladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)
Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationCytokeratin immunoprofile of primary and metastatic adenoid cystic carcinoma of salivary glands: a report of two cases
Article / Clinical Case Report Cytokeratin immunoprofile of primary and metastatic adenoid cystic carcinoma of salivary glands: a report of two cases Cibele Pidorodeski Nagano a, Cláudia Malheiros Coutinho-Camillo
More informationCase Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor
Case Reports in Medicine Volume 2015, Article ID 742920, 4 pages http://dx.doi.org/10.1155/2015/742920 Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor Omer Alici,
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationInvasive Papillary Breast Carcinoma
410 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
More informationMetastatic mechanism of spermatic cord tumor from stomach cancer
Int Canc Conf J (2013) 2:191 195 DOI 10.1007/s13691-013-0-9 CANCER BOARD CONFERENCE Metastatic mechanism of spermatic cord tumor from stomach cancer Masahiro Seike Yoshikazu Kanazawa Ryuji Ohashi Tadashi
More informationPartial Cystectomy for Invasive Bladder Cancer
European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen
More informationCase Report Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder Treated with Partial Cystectomy: A Case Report and Review of the Literature
Hindawi Case Reports in Urology Volume 2017, Article ID 6829692, 4 pages https://doi.org/10.1155/2017/6829692 Case Report Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder Treated with Partial
More informationDa Costa was the first to coin the term. Marjolin s Ulcer: A Case Report and Literature Review. Case Report. Introduction
E-Da Medical Journal 2016;3(2):24-28 Case Report Marjolin s Ulcer: A Case Report and Literature Review Yue-Chiu Su 1, Li-Ren Chang 2 Marjolin s ulcer is an aggressive cutaneous malignancy, which is common
More informationTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas
More informationTransitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression
Case Study TheScientificWorldJOURNAL (2008) 8, 223 227 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.43 Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationCare of bladder cancer patients diagnosed in Northern Ireland 2010 & 2011 (Summary)
Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary) Bannon, F., Ranaghan, L., & Gavin, A. (2014). Care of bladder cancer patients diagnosed in 2010 & 2011 (Summary). N. Cancer Registry,
More informationBLADDER CANCER CONTENT CREATED BY. Learn more at
BLADDER CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK TO YOUR DOCTOR Table of Contents WHAT IS BLADDER CANCER? 4 TYPES OF BLADDER CANCER 5 GRADING AND STAGING 8 TREATMENT OVERVIEW
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION
More informationCase Report Five-Year Survival after Surgery for Invasive Micropapillary Carcinoma of the Stomach
Case Reports in Surgery Volume 2013, Article ID 560712, 4 pages http://dx.doi.org/10.1155/2013/560712 Case Report Five-Year Survival after Surgery for Invasive Micropapillary Carcinoma of the Stomach Shigeo
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationM-VAC (methotrexate, vinblastine, d Titlefor poor prognosis patients with ur dose intensity Author(s) HIBI, Hatsuki; OKAMURA, Kikuo; TAKA SHIMOJI, Toshio; MIYAKE, Koji Citation 泌尿器科紀要 (1997), 43(2): 89-96
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationIs partial cystectomy an oncologically viable option for primary urachal adenocarcinoma?
ORIGINAL ARTICLE Is partial cystectomy an oncologically viable option for primary urachal adenocarcinoma? Sebastian Mafeld, Nikhil Vasdev, Andrew C Thorpe Department of Urology, Freeman Hospital, Newcastle
More informationQuiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
More informationRhabdomyosarcoma. Yueh-Lan Huang, Chin-Feng Tseng, Li-King Yang, and Chen-Hua Tsai
2005 16 146-150 Rhabdomyosarcoma of the Adult Nasopharynx A Case Report Yueh-Lan Huang, Chin-Feng Tseng, Li-King Yang, and Chen-Hua Tsai Division of Oncology, Department of Internal Medicine, Cardinal
More informationRare Presentation Of Adenoidcystic Carcinoma Of External Auditory Canal With Subcutaneous Metastasis In Temporal Region
ISPUB.COM The Internet Journal of Otorhinolaryngology Volume 13 Number 2 Rare Presentation Of Adenoidcystic Carcinoma Of External Auditory Canal With Subcutaneous Metastasis In Temporal Region S Kaushik,
More informationSensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy
Ge et al. BMC Urology (2015) 15:46 DOI 10.1186/s12894-015-0037-2 RESEARCH ARTICLE Open Access Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants
More informationCase Reports in Clinical Pathology, 2015, Vol. 2, No. 4
CASE REPORT Unusual mandibular metastasis of bladder cancer in a patient and two synchronous malignancies, bladder cancer and chronic lymphocytic leukemia, in an inguinal lymph node: A case report Chrysoula
More informationGuidelines for the Management of Bladder Cancer
Guidelines for the Management of Bladder Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Version 3 and 4 Sections 5.2 and 8 updated Page 1 of 9 1. Scope of
More informationUnknown Slides Conference
Unknown Slides Conference Jae Y. Ro, MD, PhD Weill Medical College of Cornell Univ. The Methodist Hospital, and UT MD Anderson Cancer Center Houston, TX November 9, 2013 Amman, Jordan 25 th Congress of
More information